Literature DB >> 11142582

Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis.

C Mazzaro1, G Panarello, S Carniello, A Faelli, G Mazzi, M Crovatto, S Baracetti, F Nascimben, F Zorat, G Pozzato, L Faccini, L Campanacci.   

Abstract

BACKGROUND/AIMS: The association between mixed cryoglobulinaemia, cryoglobulinaemic glomerulonephritis, and chronic hepatitis C virus infection has recently been described. The renal disease had usually been treated with immunosuppressive therapy, but, given the presence of viral infection, this therapy is no longer recommended. In this study, we compare steroid vs interferon therapy in a group of patients affected by hepatitis C virus-positive cryoglobulinaemic glomerulonephritis in the stationary phase. PATIENTS/
METHODS: The diagnosis of cryoglobulinaemic glomerulonephritis was made bearing in mind standard criteria. Patients were randomly assigned to 2 groups receiving oral prednisone 0.2 mg/kg/die for 6 months (6 patients, group A) or lymphoblastoid interferon 3 MU, three times a week for 6 months [7 patients, group B). Hepatitis C virus-RNA was determined by reverse transcription-polymerase chain reaction and hepatitis C virus genotype according to Okamoto. Hepatitis C virus-RNA quantitation was performed by competitive polymerase chain reaction. RESULTS; The 2 groups were comparable in terms of age and severity of kidney failure. All genotypes of hepatitis C virus were found with a prevalence of Type 1b. In group A, 4 patients showed a partial response; in group B, 1 patient achieved complete remission, 4 a partial response, 2 patients in both groups showed no response. At the end of the treatment, all patients in both groups relapsed. Only 1 patient in group B became hepatitis C virus-RNA negative, and recovered from cryoglobulinaemic glomerulonephritis.
CONCLUSIONS: Interferon seems to be an effective drug in the treatment of cryoglobulinaemic glomerulonephritis, but dosage and length of treatment still need to be addressed by large multicentre studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11142582     DOI: 10.1016/s1590-8658(00)80335-7

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

Review 1.  Autoimmune manifestations in viral hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Semin Immunopathol       Date:  2012-07-28       Impact factor: 11.759

Review 2.  Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.

Authors:  Nuria Montero; Alexandre Favà; Eva Rodriguez; Clara Barrios; Josep M Cruzado; Julio Pascual; Maria Jose Soler
Journal:  Cochrane Database Syst Rev       Date:  2018-05-07

Review 3.  Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.

Authors:  Michiko Shimada; Norio Nakamura; Tetsu Endo; Hideaki Yamabe; Masayuki Nakamura; Reiichi Murakami; Ikuyo Narita; Hirofumi Tomita
Journal:  BMC Nephrol       Date:  2017-03-29       Impact factor: 2.388

Review 4.  Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence.

Authors:  Fabrizio Fabrizi
Journal:  Scientifica (Cairo)       Date:  2012-07-08

5.  Chapter 9: Infection-related glomerulonephritis.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.